Immunobiologic agents for the treatment of psoriasis: Clinical research delivers new hope for patients with psoriasis

Archives of Dermatology

Volumn 139, Issue 6, 2003, Pages 791-793

  Gottlieb, Alice ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; DACLIZUMAB; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; IMMUNOLOGIC AGENT; INFLIXIMAB; SIPLIZUMAB;

DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE; LYMPHOCYTE COUNT; PAIN; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; RHINITIS; SCORING SYSTEM;

BIOLOGICAL THERAPY; HUMANS; PSORIASIS; RECOMBINANT FUSION PROTEINS;

EID: 0038459338     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.6.791     Document Type: Editorial

References (33)

1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol. 2001;137:280-284.
2. Gottlieb AB. Psoriasis. Dis Manage Clin Outcome. 1998;1:195-202.
3. Gottlieb AB. Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J Invest Dermatol. In press.
4. Gottlieb AB. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol. 2002;105:105-116.
5. Gottlieb AB. Psoriasis: immunopathologyand immunomodulation. Dermatol Clin. 2001;19:649-657.
6. Krueger GG, Patt KA, Strough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833.
7. Ellis CN, Krueger GG, Group AC. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-255.
8. Ory P, Sharp JT, Salonen D, et al. Etanercept (ENBREL) inhibits radiographic progression in patients with psoriatic arthritis [abstract]. Arthritis Rheum. 2002;46:442.
9. Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum. 2001;44:S90.
10. Gottlieb AB, Vaishnaw AK. Alefacept (Amevive) does not blunt primary or secondary immune responses [abstract]. Arthritis Rheum. 2001;44:S91.
11. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002;46:2776-2784.
12. Gottlieb AB. Psoriatic arthritis: a guide for dermatology nurses. Dermatol Nurs. In press.
13. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829-830.
14. Chaudhad U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-1847.
15. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-390.
16. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. In press.
17. Gottlieb AB, Matheson RT, Lowe NJ, Zitnik RG. Efficacy of enbrel in patients with psoriasis [abstract]. J Invest Dermatol. 2002;119:234.
18. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy. J Clin Invest. 1998;101:783-794.
19. Trepicchio W, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively down-regulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999;104:1527-1523.
20. Thomas P. IL-4-induced immune deviation as therapy of psoriasis [abstract]. Arch Dermatol Res. 2001;293:30.
21. Gottlieb AB, Castle TB, Frankel E, et al. Primary and secondary immune responses are maintained in psoriasis patients receiving alefacept. J Am Acad Dermatol. In press.
22. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000;42:428-435.
23. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138:591-600.
24. Papp KB, Bissonnette R, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol. 2001;45:665-674.
25. Gottlieb A, Lebwohl M, Totoritis M, et al. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol. 2002;47:692-700.
26. Abrams J, Kelley S, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000;192:681-694.
27. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103:1243-1252.
28. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 2000;43:448-458.
29. Gottlieb SL, Gilleaudeau P,Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1995;1:442-447.
30. Gottlieb AB, Bacha P, Parker K, Strand V. Use of the interleukin-2 fusion protein, DA8389IL-2, for the treatment of psoriasis. Dermatol Ther. 1998;5:48-63.
31. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CEM, for the Alefacept Clinical Study Group. An international, randomized, doubleblind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
32. Gottlieb AB. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. In press.
33. Frederiksson T, Pettersson U. Severe psoriasis oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.